Regulatory approvals and market developments across our core therapeutic categories: Hepatitis B/C, HIV, Oncology, Erectile Dysfunction, and Veterinary medicine.
Gilead's Bixlenvo combines bictegravir 75mg and lenacapavir 50mg into the smallest once-daily single-tablet regimen for virologically suppressed HIV patients, offering the first single-tablet option for patients unable to take currently available regimens. A meaningful new option for treatment-experienced HIV patients.
Approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy — a RAS GTPase inhibitor addressing a historically hard-to-treat cancer.
Approved in combination with chemotherapy and tislelizumab as first-line treatment for adults with HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. Expands first-line options in HER2+ GI cancers.
